An EHR-based Platform To Facilitate Outcomes and Research Methods in Cerebrovascular Diseases
PLATFORM-CVD
A Platform for Linking and Assessing To Facilitate Outcomes and Research Methods in CerebroVascular Diseases Using Electronic Health Records (PLATFORM-CVD)
1 other identifier
observational
300,000
1 country
1
Brief Summary
In this protocol, the investigators present methods and preliminary results from the PLATFORM-CVD Study, an EHR-based multicenter cohort. This study will focus on assessing the distribution of major cerebrovascular diseases, determining the risk factors associated with disease incidence and worse in-hospital outcomes, as well as describing the quality of care. Data from this cohort will be used to develop suitable prediction models for cerebrovascular diseases using real-world data and to understand how outcomes for cerebrovascular diseases would change with quality improvement interventions.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2018
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2020
CompletedFirst Submitted
Initial submission to the registry
February 5, 2021
CompletedFirst Posted
Study publicly available on registry
March 1, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2021
CompletedMarch 1, 2021
February 1, 2021
3 years
February 5, 2021
February 26, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
In-hospital mortality
Patients who died during hospitalization due to cerebrovascular diseases
From date of hospitalization until the date of discharge, assessed up to 90 days
Length of stay at hospital
The total days for a patients with cerebrovascular diseases at hospitalization
From date of hospitalization until the date of discharge, assessed up to 90 days
Costs
The total costs for a patients with cerebrovascular diseases at hospitalization
From date of hospitalization until the date of discharge, assessed up to 90 days
Secondary Outcomes (21)
Rate of antiplatelet medication use
From date of hospitalization until the date of discharge, assessed up to 90 days
Rate of dual antiplatelet medication use for non-disabling IS and TIA events
From date of hospitalization until the date of discharge, assessed up to 90 days
Rate of DVT prophylaxis ≤ 48 hours
48 hours within hospitalization
Cerebrovascular assessment ≤ seven days
7 days within hospitalization
Statin therapy for LDL ≥100 mg/dL during hospitalization
From date of hospitalization until the date of discharge, assessed up to 90 days
- +16 more secondary outcomes
Eligibility Criteria
Twenty-five hospitals were enrolled in the PLATFORM-CVD Study between January 1st, 2017 and May 20th, 2020. Hospitals were included if they: 1) had neurological wards; 2) were secondary or tertiary hospitals; 3) could admit at least 20 cerebrovascular disease patients every month.
You may qualify if:
- Patients were included in the registry if they were hospitalized with a primary diagnose of：
- cerebral infarction (I63)
- nontraumatic intracerebral hemorrhage (I61)
- nontraumatic subarachnoid hemorrhage (I60)
- transient cerebral ischemic attack and related syndromes (G45)
- intracranial and intraspinal phlebitis and thrombophlebitis (G08)
- vascular dementia (F01)
- other aneurysms (I72)
You may not qualify if:
- Patients diagnosed with other diseases.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Ministry of Science and Technology of the People´s Republic of Chinalead
- Dalian Jiuzhou Century Hospitalcollaborator
- Dengzhou Central Hospitalcollaborator
- Guangxi Ruikang Hospitalcollaborator
- Guangdong Second Provincial General Hospitalcollaborator
- Handan Central Hospitalcollaborator
- Xunxian People's Hospitalcollaborator
- Kaifeng Central Hospitalcollaborator
- Laoling People's Hospitalcollaborator
- New Area People's Hospital of Luoyangcollaborator
- Chinese Traditional Medicine Hospital of Meishancollaborator
- Mengjin People's Hospitalcollaborator
- Nanyang Central Hospitalcollaborator
- Hexigten Banner Mongolian Traditional Chinese Medicine Hospitalcollaborator
- Inner Mongolian Hospital of Traditional Chinese Medicinecollaborator
- The Affiliated Hospital of Qingdao Universitycollaborator
- Renqiu Kangjixintu Hospitalcollaborator
- Shenzhen Second People's Hospitalcollaborator
- Wuhan No.1 Hospitalcollaborator
- Xingtai City Ninth Hospitalcollaborator
- Yilong People's Hospitalcollaborator
- Yongcheng City Central Hospitalcollaborator
- Chongqing Donghua Hospitalcollaborator
- The Second Affiliated Hospital of Luohe Medical Collegecollaborator
Study Sites (1)
Beijing Tiantan Hospital
Beijing, Beijing Municipality, 100070, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Zi-Xiao Li, PhD
Beijing Tiantan Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 12 Months
- Sponsor Type
- OTHER GOV
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
February 5, 2021
First Posted
March 1, 2021
Study Start
January 1, 2018
Primary Completion
December 31, 2020
Study Completion
December 31, 2021
Last Updated
March 1, 2021
Record last verified: 2021-02
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP
- Time Frame
- The data will be available when the data collection finished.
We will share the data dictionary of the study. The data could be applied by the PI's email. Applicant should make an SAP first. The PI will check the SAP and appoint a statistician for the analysis.